Signed in as:
filler@godaddy.com
Join Cold Agglutinin Disease Foundation in Changing Lives
The goal of this clinical study is to evaluate povetacicept (ALPN-303) in adults with autoimmune cytopenias of immune thrombocytopenia, autoimmune hemolytic anemia, and cold agglutinin disease to determine if povetacicept is safe and potentially beneficial in treating these diseases. During the study treatment period participants will receive povetacicept approximately every 4 weeks for 6 months, with the possibility of participating in a 6-month study treatment extension period.
Alpine Immune Sciencies
Alpine Immune Sciences is a clinical stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based immunotherapies.
This is a multinational, multi-center, observational, prospective, longitudinal disease registry designed to collect data on participants with cold agglutinin disease (CAD) or cold agglutinin syndrome (CAS). Among them, a minimum of 30 patients with CAD treated with sutimlimab are expected to take part in the sutimlimab cohort study.
Active, Recruiting - Click Here
Find a Sanofi Clinical Trial
Welcome to Sanofi Clinical Trials. Their goal is to help you find out about Sanofi’s research studies into potential new treatments and vaccines. Looking for research into a specific condition? You can use the search function to find a clinical trial near you. Click Here
Here are 2 studies listed below:
Cold Agglutinin Disease Real World Evidence Registry (CADENCE)
We are writing to introduce ourselves and to share some exciting cold agglutinin disease (CAD) news. Apellis is a development stage, global biopharmaceutical company that was established 10 years ago to combine courageous science, creativity, and compassion to deliver life-changing medicines for a broad range of serious diseases.
For clinical trial information, please email clinicaltrials@apellis.com
A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD) Swedish Orphan Biovitrum. Click Here
Active, Recruiting Last Updated Post March 7, 2022 Estimated Completion Date June 2024
A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with Cold Agglutinin Disease (CAD)
Brief Summary:
Phase 3 - The purpose of the study is to determine the efficacy of pegcetacoplan administration compared to placebo in increasing hemoglobin (Hgb) level from baseline and avoiding transfusion in participants with primary cold agglutinin disease (CAD).
Efficacy, Safety and Pharmacokinetics of Rilizabrutinib in Patients with Warm Autoimmue Hemolytic Anemia (wAIHA) This is a single group treatment, Phase 2 open-label, study to evaluate the efficacy, safety and pharmacokinetics of rilizabrutinib in adult patients with wAIHA.
As of September 29, 2021 Active, Not Recruiting YET
Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmunce Hemolytic Anemia (wAIHA). Part A: To evaluate the safety and tolerability of subcutaneous injections of isatuximab in adults with wAIHA Part B: To evaluate the efficacy of the selected dose in adults with wAIHA
Active, Recruiting
